I would just say that in the conversations we have....
I guess I'll start back at the beginning. Normally when we're purchasing drugs, we make an order and we get the drugs. There aren't many other steps in that process. When you have to go through the CAMR process, there are about 30 other steps in that process. There is a stunning diagram that demonstrates what that comparison is.
Countries have told us, “We don't even understand the legislation, so how can we go forward with this?” There are enormous barriers in there. I mean, we can speak about what Apotex would say. We know from the other side that there is another initiation of that process that has to happen also from the countries' perspective. The countries are not going to move forward with it. They're not here to testify. They weren't invited to testify. No criticism to the committee, but Apotex is not here, and was unavailable today.
The countries' perspective, as they told it to us and as they experienced it with us, was this: the system was unworkable and it needed to be changed.